Loading stock data…
$2.89-0.27 (-8.54%)
Apimeds Pharmaceuticals US, Inc.
Apimeds Pharmaceuticals US, Inc. in the Healthcare sector is trading at $2.89 with a market capitalization of $7M. The stock is currently near its 52-week low of $1.51, remaining 74.3% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$6.28M↑ | -$12.19M↓ | -$7.04M↓ | -$1.84M↑ | -$2.66M |
| Net Income | -$20.17M↑ | -$35.06M↓ | -$1.16M↑ | -$1.78M↑ | -$2.66M |
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Insc...